Jabil Launches Jabil Healthcare, the Largest Healthcare Manufacturing Solutions Provider
Jabil Inc. (NYSE: JBL) today announced the consolidation of its entire healthcare organization under Jabil Healthcare, led by Steve Borges, CEO and EVP. Jabil Healthcare combines, under a single umbrella, Nypro with its Orthopedics, Spine, Trauma and associated medical instruments operations. With more than 35 global sites and nearly 20,000 employees serving the leading brands in healthcare, this powerful combination makes Jabil the largest healthcare manufacturing solutions provider.
Jabil Healthcare serves five key sectors in the healthcare market: medical devices, orthopedics, diagnostics, pharmaceutical delivery systems, and consumer health. In each arena, demand for value-based care solutions is forcing significant changes in the evolution of healthcare products and services and driving digital health innovations. Taking center stage are Internet of Things (IoT) and digital health platform innovations enabled by connectivity, sensors and miniaturization.
“By harnessing the power of the Jabil and Nypro teams, we are in the unique position to accelerate technology advancements and augment the value we bring to our customers, their patients and the healthcare industry,” said Borges. “With the rise of digital health and additive manufacturing, the time is right to unite our diverse capabilities and domain expertise under one strong brand.”
Jabil Healthcare unifies the company’s medical industry know-how with deep cross-sector experience in injection molding, electronics, sensor integration, and additive manufacturing to help healthcare brands accelerate and scale technology advancements. This integrated line of capabilities across Jabil is brought to bear for its base of healthcare customers, from emerging startups to global enterprises.
The support of women’s technology company, Elvie, is just one example. “We're in the connected health space, which is actually quite a new area. We needed expertise in everything from hardware to firmware to software,” said Tania Boler, CEO of Elvie, in a Jabil Healthcare case study released today. “When we tried to select the best in class manufacturing partner for us, to be honest, Jabil was the no-brainer solution because they have had so much experience across so many different partners in so many different product categories.”
“With more than 50 years of expertise, Jabil Healthcare is well versed in integrating components and subsystems into pharmaceutical, orthopedic, diagnostic, medical and consumer healthcare devices,” Borges said. “As a united team with a clear mission, we are powerfully positioned to help our customers deliver high-quality, innovative products and services that improve patient outcomes.”
About Jabil
Jabil (NYSE: JBL) is a manufacturing solutions provider that delivers comprehensive design, manufacturing, supply chain and product management services. Leveraging the power of over 200,000 people across 100 sites strategically located around the world, Jabil simplifies complexity and delivers value in a broad range of industries, enabling innovation, growth and customer success. For more information, visit jabil.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005387/en/
Contact information
North America:
Erin Vadala
Warner Communications
978-468-3076
erin@warnerpr.com
Europe, Middle East and Africa:
Kirsten Oosterhof
+44 (0)1506 447215
Kirsten_Oosterhof@Jabil.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 15:00:00 EEST | Press release
To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this manual process demands significant time and effort and can lead to inconsistent results,” said Dr. A
Pure Lithium Founder & CEO Emilie Bodoin Recognized for Trailblazing Woman of the Year at 2025 Volta Foundation Awards at 17 th Annual Fastmarkets Lithium Supply and Battery Raw Materials Conference27.6.2025 13:00:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that its Founder, Chairman & CEO, Emilie Bodoin received special recognition for Trailblazing Woman of the Year Award Sponsored by ExxonMobil at the 2025 Fastmarkets Volta Awards Ceremony, in Las Vegas, Nevada on June 24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627170164/en/ This award celebrates an exceptional female leader who has demonstrated outstanding leadership, vision, and impact within her industry. It recognizes achievements in driving innovation, fostering diversity, and inspiring others while making significant contributions to her organization. “I am truly honored to receive special recognition for this award. One of the best things about my role is the opportunity to lead by example and encourage and inspire women and girls who may not yet recognize their potential. To all of m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom